vs
礼蓝动物保健（ELAN）与帕兰提尔科技（PLTR）财务数据对比。点击上方公司名可切换其他公司
帕兰提尔科技的季度营收约是礼蓝动物保健的1.2倍（$1.4B vs $1.1B），帕兰提尔科技净利率更高（43.3% vs -24.1%，领先67.4%），帕兰提尔科技同比增速更快（70.0% vs 12.2%），帕兰提尔科技自由现金流更多（$764.0M vs $46.0M），过去两年帕兰提尔科技的营收复合增速更高（48.9% vs -2.6%）
礼蓝动物保健是一家美国动物保健制药企业，专注于生产宠物及家畜用药品与疫苗。该公司原为礼来公司旗下子公司，2019年完成分拆独立，目前是全球第三大动物保健企业。
帕兰提尔科技是美国上市企业，专注研发数据集成与分析平台，为政府机构、军方及各行业企业提供多源数据整合分析能力。旗下核心产品Gotham与Foundry可打通相互孤立的数据库，广泛支撑情报作业、反恐分析、执法工作及企业级数据分析场景。
ELAN vs PLTR — 直观对比
营收规模更大
PLTR
是对方的1.2倍
$1.1B
营收增速更快
PLTR
高出57.8%
12.2%
净利率更高
PLTR
高出67.4%
-24.1%
自由现金流更多
PLTR
多$718.0M
$46.0M
两年增速更快
PLTR
近两年复合增速
-2.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.4B |
| 净利润 | $-276.0M | $608.7M |
| 毛利率 | 51.5% | 84.6% |
| 营业利润率 | -22.6% | 40.9% |
| 净利率 | -24.1% | 43.3% |
| 营收同比 | 12.2% | 70.0% |
| 净利润同比 | -3350.0% | 670.4% |
| 每股收益（稀释后） | $-0.55 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELANPLTR
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.2B | $1.0B | ||
| Q1 25 | $1.2B | $883.9M | ||
| Q4 24 | $1.0B | $827.5M | ||
| Q3 24 | $1.0B | $725.5M | ||
| Q2 24 | $1.2B | $678.1M | ||
| Q1 24 | $1.2B | $634.3M |
净利润ELANPLTR
| Q4 25 | $-276.0M | $608.7M | ||
| Q3 25 | $-34.0M | $475.6M | ||
| Q2 25 | $11.0M | $326.7M | ||
| Q1 25 | $67.0M | $214.0M | ||
| Q4 24 | $-8.0M | $79.0M | ||
| Q3 24 | $364.0M | $143.5M | ||
| Q2 24 | $-50.0M | $134.1M | ||
| Q1 24 | $32.0M | $105.5M |
毛利率ELANPLTR
| Q4 25 | 51.5% | 84.6% | ||
| Q3 25 | 53.4% | 82.4% | ||
| Q2 25 | 57.5% | 80.8% | ||
| Q1 25 | 57.3% | 80.4% | ||
| Q4 24 | 50.9% | 78.9% | ||
| Q3 24 | 52.2% | 79.8% | ||
| Q2 24 | 58.2% | 81.0% | ||
| Q1 24 | 57.3% | 81.7% |
营业利润率ELANPLTR
| Q4 25 | -22.6% | 40.9% | ||
| Q3 25 | -4.4% | 33.3% | ||
| Q2 25 | 2.0% | 26.8% | ||
| Q1 25 | 5.0% | 19.9% | ||
| Q4 24 | -5.0% | 1.3% | ||
| Q3 24 | 54.3% | 15.6% | ||
| Q2 24 | -2.7% | 15.5% | ||
| Q1 24 | 1.0% | 12.8% |
净利率ELANPLTR
| Q4 25 | -24.1% | 43.3% | ||
| Q3 25 | -3.0% | 40.3% | ||
| Q2 25 | 0.9% | 32.6% | ||
| Q1 25 | 5.6% | 24.2% | ||
| Q4 24 | -0.8% | 9.5% | ||
| Q3 24 | 35.3% | 19.8% | ||
| Q2 24 | -4.2% | 19.8% | ||
| Q1 24 | 2.7% | 16.6% |
每股收益（稀释后）ELANPLTR
| Q4 25 | $-0.55 | $0.24 | ||
| Q3 25 | $-0.07 | $0.18 | ||
| Q2 25 | $0.02 | $0.13 | ||
| Q1 25 | $0.13 | $0.08 | ||
| Q4 24 | $-0.01 | $0.03 | ||
| Q3 24 | $0.73 | $0.06 | ||
| Q2 24 | $-0.10 | $0.06 | ||
| Q1 24 | $0.06 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $545.0M | $7.2B |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $6.5B | $7.4B |
| 总资产 | $13.4B | $8.9B |
| 负债/权益比越低杠杆越低 | 0.60× | — |
8季度趋势，按日历期对齐
现金及短期投资ELANPLTR
| Q4 25 | $545.0M | $7.2B | ||
| Q3 25 | $505.0M | $6.4B | ||
| Q2 25 | $539.0M | $6.0B | ||
| Q1 25 | $487.0M | $5.4B | ||
| Q4 24 | $468.0M | $5.2B | ||
| Q3 24 | $490.0M | $4.6B | ||
| Q2 24 | $416.0M | $4.0B | ||
| Q1 24 | $345.0M | $3.9B |
总债务ELANPLTR
| Q4 25 | $3.9B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.8B | — |
股东权益ELANPLTR
| Q4 25 | $6.5B | $7.4B | ||
| Q3 25 | $6.7B | $6.6B | ||
| Q2 25 | $6.8B | $5.9B | ||
| Q1 25 | $6.4B | $5.4B | ||
| Q4 24 | $6.1B | $5.0B | ||
| Q3 24 | $6.5B | $4.5B | ||
| Q2 24 | $5.9B | $4.1B | ||
| Q1 24 | $6.1B | $3.8B |
总资产ELANPLTR
| Q4 25 | $13.4B | $8.9B | ||
| Q3 25 | $13.6B | $8.1B | ||
| Q2 25 | $13.7B | $7.4B | ||
| Q1 25 | $12.9B | $6.7B | ||
| Q4 24 | $12.6B | $6.3B | ||
| Q3 24 | $13.3B | $5.8B | ||
| Q2 24 | $13.8B | $5.2B | ||
| Q1 24 | $14.0B | $4.8B |
负债/权益比ELANPLTR
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — | ||
| Q1 24 | 0.95× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $108.0M | $777.3M |
| 自由现金流经营现金流 - 资本支出 | $46.0M | $764.0M |
| 自由现金流率自由现金流/营收 | 4.0% | 54.3% |
| 资本支出强度资本支出/营收 | 5.4% | 0.9% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $284.0M | $2.1B |
8季度趋势，按日历期对齐
经营现金流ELANPLTR
| Q4 25 | $108.0M | $777.3M | ||
| Q3 25 | $219.0M | $507.7M | ||
| Q2 25 | $237.0M | $539.3M | ||
| Q1 25 | $-4.0M | $310.3M | ||
| Q4 24 | $177.0M | $460.3M | ||
| Q3 24 | $162.0M | $419.8M | ||
| Q2 24 | $200.0M | $144.2M | ||
| Q1 24 | $2.0M | $129.6M |
自由现金流ELANPLTR
| Q4 25 | $46.0M | $764.0M | ||
| Q3 25 | $127.0M | $500.9M | ||
| Q2 25 | $180.0M | $531.6M | ||
| Q1 25 | $-69.0M | $304.1M | ||
| Q4 24 | $130.0M | $457.2M | ||
| Q3 24 | $120.0M | $415.8M | ||
| Q2 24 | $166.0M | $141.3M | ||
| Q1 24 | $-22.0M | $126.9M |
自由现金流率ELANPLTR
| Q4 25 | 4.0% | 54.3% | ||
| Q3 25 | 11.2% | 42.4% | ||
| Q2 25 | 14.5% | 53.0% | ||
| Q1 25 | -5.8% | 34.4% | ||
| Q4 24 | 12.7% | 55.3% | ||
| Q3 24 | 11.7% | 57.3% | ||
| Q2 24 | 14.0% | 20.8% | ||
| Q1 24 | -1.8% | 20.0% |
资本支出强度ELANPLTR
| Q4 25 | 5.4% | 0.9% | ||
| Q3 25 | 8.1% | 0.6% | ||
| Q2 25 | 4.6% | 0.8% | ||
| Q1 25 | 5.4% | 0.7% | ||
| Q4 24 | 4.6% | 0.4% | ||
| Q3 24 | 4.1% | 0.5% | ||
| Q2 24 | 2.9% | 0.4% | ||
| Q1 24 | 2.0% | 0.4% |
现金转化率ELANPLTR
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 1.07× | ||
| Q2 25 | 21.55× | 1.65× | ||
| Q1 25 | -0.06× | 1.45× | ||
| Q4 24 | — | 5.83× | ||
| Q3 24 | 0.45× | 2.92× | ||
| Q2 24 | — | 1.08× | ||
| Q1 24 | 0.06× | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
PLTR
| Geographic Concentration Risk | $1.1B | 77% |
| Other | $330.4M | 23% |
